Moderna Surges Over 60%, Merck Jumps on Late-Stage Cancer Vaccine Trial Success
Moderna shares soared over 60% on Wednesday, and Merck also rallied sharply, after the two companies announced impressive results from a late-stage trial of a cancer vaccine for…
Moderna shares soared over 60% on Wednesday, and Merck also rallied sharply, after the two companies announced impressive results from a late-stage trial of a cancer vaccine for melanoma patients. The positive news drove a significant rise in both companies' stock prices.
insigtX content is informational and educational, not investment advice.